Oncology Institute (DFPH) Common Equity (2019 - 2026)

Oncology Institute has reported Common Equity for 8 years, with the latest figure at -$16.3 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 421.27% year-over-year to -$16.3 million; the trailing twelve-month figure through Mar 2026 stood at -$16.3 million (down 421.27% YoY), and the FY2025 full-year result was -$15.7 million, down 538.01% from the prior year.
• Common Equity for Q1 2026 stood at -$16.3 million, down from -$15.7 million in the prior quarter.
• The five-year high for Common Equity was $132.0 million in Q1 2022, with the low at -$16.3 million in Q1 2026.
• Historically, Common Equity has averaged $50.6 million across 5 years, with a median of $41.3 million in 2024.
• Annual changes were most pronounced in 2022 — Common Equity soared 179.98% — and 2025, when it sank 538.01%.
• Oncology Institute's Common Equity stood at $123.2 million in 2022, then plunged by 53.7% to $57.0 million in 2023, then sank by 93.71% to $3.6 million in 2024, then slumped by 538.01% to -$15.7 million in 2025, then fell by 3.59% to -$16.3 million in 2026.
• The last three Common Equity figures came in at -$16.3 million (Q1 2026), -$15.7 million (Q4 2025), and -$12.3 million (Q3 2025), per Business Quant data.